The curtain is coming down on Broadway's 'Death Becomes Her', a campy musical adaptation of the 1992 cult classic film. After a 20-month run and 650 performances, the show will conclude on June 28, failing to recoup its massive $31.5 million investment. This is a stark reminder of the challenges faced by new musicals in achieving profitability, with only a handful of recent productions managing to turn a profit. But what makes 'Death Becomes Her' particularly intriguing is its journey from Broadway to a North American tour, offering a second chance at success.
The show, which opened at the Lunt-Fontanne Theatre in November 2024, received positive reviews and was nominated for 10 Tony Awards, the most of any show in the 2024-2025 season. Megan Hilty and Jennifer Simard, both Tony-nominated for their comedic performances, took on roles originally played by Meryl Streep and Goldie Hawn in the film. Their portrayal of frenemies on a quest for eternal youth, with a healthy dose of rivalry, was a highlight for many.
However, the show's critical acclaim and awards didn't translate into commercial success. The effects-heavy production, while visually stunning, may have been a challenge for some audiences, and the lack of a clear, relatable message could have been a factor in its box office performance. Despite this, the show's creative team remains optimistic, with Universal Theatrical Group's senior VP of creative and strategy, Lowe Cunningham, expressing pride in the production's impact and excitement for its future as a touring show.
The North American tour, set to launch in September at Playhouse Square in Cleveland, Ohio, offers a second chance for the show to connect with audiences across the country. It's a testament to the resilience of the performing arts industry and the enduring appeal of a well-crafted story, even if it doesn't initially resonate with a broad audience. The tour also provides an opportunity for the show to find its niche and build a dedicated fan base.
In my opinion, 'Death Becomes Her' is a fascinating case study in the challenges and opportunities of adapting a cult classic into a musical. The show's initial failure to recoup its investment highlights the risks involved in such ventures, but the potential for a successful tour suggests that the right combination of storytelling, performance, and marketing can overcome these challenges. It's a reminder that sometimes, a second act is all you need.
